Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PP405 in adult females with androgenetic alopecia
NCT07907783Phase 2Not yet recruiting
- Sponsor
- Pelage Pharmaceuticals
- Start
- Nov 2026
- Primary completion
- Sep 2027
01
Overview
Phase 2, randomised, double-blind trial of PP405 topical vehicle gel in androgenetic alopecia (AGA) (2 arms), sponsored by Pelage Pharmaceuticals. Primary endpoint: Non-vellus target area hair count at 24 weeks. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
PP405 topical vehicle gel
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on NCT07907783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07907783.